By Michelle Fay Cortez, Anna Edney and James Paton
Concern over Novartis AG’s corporate culture returned to the spotlight after U.S. regulators said the Swiss drugmaker delayed disclosing manipulation...
We have updated our privacy policy to be more clear and meet the new requirements of the GDPR. By continuing to use our site, you accept our revised Privacy Policy.
